GPAS is now part of EIT Pathogena, a cutting-edge genomic analysis platform for academics and public health professionals around the world to help fight infectious diseases.

A new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.

Harnessing the power of CRISPR to develop the next generation of RNA therapeutics.

Developing innovative therapeutics in oncology and behavioural brain disorders.

Developing treatments using molecularly targeted drugs tailored to the specific molecular profile of a patient's tumour.

Developing monoclonal antibodies for instant, long-lasting immunity, protecting vulnerable people from infectious diseases.

Developing small-molecule drugs targeting cancer-linked disordered proteins.

Commercialising T cell receptor-based immunotherapy for multiple indications.

MatchBio's technology can improve the function of antigen receptors, for example by tuning their antigen sensitivity of their existing products.

The advancement, through pre-clinical and clinical trials, the development a number of lentiviral-based gene therapies for respiratory diseases.

The company is focused on the use of bacteriocins and anti-microbial therapies.

Company developing a new gene therapy products for the treatment of rare diseases.

Cancer diagnostics.

A proprietary multi-omics discovery platform to resolve RNA-centric mechanisms in rare and chronic diseases.

Digital CBTe software.

Design oligonucleotide drugs that can activate expression of specific genes using a novel gene regulatory mechanism.

Optical neural networks.

To discover significantly de-risked novel drug targets for licensing and in-house development.

To develop and commercialise a rapid non-lab based diagnostic test for viral infections, with the first focus on Covid19.

To develop new methodologies for single cell genomics.

Development and characterisation of novel, first-in-class, selective and potential small molecule inhibitors targeting the YEATS Domain (YD) of MLLT1 and MLLT3.

To develop therapeutic antibodies.

The company has been created by the Dementia Discovery Fund. The Company’s mission is to develop disease-modifying therapeutics that restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease and other dementias.

To develop a bioelectronic platform with an initial focus on treating urinary incontinence.

LiliumX uses a unique protein technology platform to facilitate scalable discovery of first-in-class bispecific biologics

First commercial producer of sustainable, guilt-free meat.

The technology consists of two patent families which collectively enable the development of cost effective, off-the-shelf vaccines based on a proprietary dendritic cell subset for the treatment of solid tumour cancers. The technology overcomes certain key roadblocks previously associated with dendritic cell vaccine technology.

Cleaner, safer, faster chemical production.

Drug Development. Oxford Asymmetry merges with Evotec BioSystems April 2009.

Gene-based Therapeutics.

Pharmaceuticals.

Neurodegenerative diseases.

Antibiotics.

Immunology.

Drug Design.

Anti-cancer drugs.

Modification of proteins.

Glycosolation technology.

Duchenne Muscular Dystrophy.

Method for ranking/selecting mitochondrial neoantigens for targeted cell therapy.

A novel cancer cell therapy company, delivering tumour-targeted expression of anti-cancer biologics.

Developing novel catalyst process and route to high value internal olefins.

Crop biostimulants for global food security

Produce non-replicating bacterial cells for a variety of healthcare applications.

DNA methylation detection using this TAPS technology. Base Genomics was acquired by Exact Sciences in October 2020.

Platform technology based on NG capture-c technique computational pipelines and experimental know-how.

DNA assembly.

GryeOx addresses significant unmet need in drug discovery as the IP can make expanded drug libra of macrocycles in the hit to lead stage.

Specialising in biotechnology. In 2006 Avidex was acquired by Medigene AG.

Chemical genomics.

Biomimetic spinning of fibres.

Screensavers for drug candidates.

A biologics company with a mission to treat a range of autoimmune and inflammatory disorders.

Biopharmaceutical company treating patients with chronic infectious diseases and cancer. In 2007 Oxxon Therapeutics was acquired by Oxford BioMedica plc.

Pharmaceutical services. In 2009 Sense Proteomics Ltd was acquired by Oxford Gene Technology (OGT).

DNA technology

Software and patented approach to differential diagnosis of cognitive diseases

OxStem Beta will generate novel therapies to stimulate formation of new beta cells in the pancreas
(neogenesis) by targeting pathways that are normally only active during development or following
pancreatic injury.

OxStem Immuno aims to develop small molecule drugs that augment macrophage efferocytosis in
vitro and enhance tissue repair in vivo. These therapies will supercede the need for cell transplantation
or cytokine therapy in the context of tissue repair for chronic wounds and a range of inflammatory
conditions.

Developing immunotherapies that can potentially transform cancer treatment.

Focus on the synthesis of natural products.

Developing a brain implant to treat a variety of diseases.

Development and application of bacterial biosensors for detection and quantification of environmental contamination, including organics and metals, on-site and in real-time.

Developing mass photometry - a revolutionary new way to analyse molecules. It enables the accurate mass measurement of single molecules in solution, in their native state and without the need for labels.

Therapeutics biotech company developing proprietary drug delivery platform technology.

Pre-clinical stage biotechnology company which aims to deliver innovative cancer care to patients.

The company is developing novel technology with applications in plant protection products.

Exploitation of proprietary ‘Cell seq’ Technology platform

Pioneering a powerful new approach to generate vaccines.

Software enabled system for orthopaedic care pathway management, implant safety monitoring and patient reported outcome delivery.

Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

EnzBond aims to change the current understanding of enzyme evolution process.

The development of cancer drugs that reprogram cancer cells to undergo the body's natural process of cell death.

Researches, designs and will market diagnostic tests for the measurement of clinical bio markers that reduce healthcare costs and improve patient outcomes.

OxStem is a developer of cell programming therapies.

EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.

The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer.

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. In 2021, Oxford Immunotec was acquired by PerkinElmer.

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.

Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins.

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

TdeltaS is committed to developing science-based proprietary products that sit at the interface of food and pharmaceuticals - nutraceuticals - and offer real improvement in human physical and mental performance.

Particle Therapeutics is a drug delivery company developing innovative particle formulation and drug delivery technologies to improve the efficacy and administration of a range of pharmaceuticals.

ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.

Oxford BioDynamics offers a novel and revolutionary biomarker discovery platform technology in the diagnostics field of aberrant gene expression.

Crysalin develop a protein lattice technology that is founded on a novel form of highly ordered materials, crysalins, that are produced through modification of naturally occurring protein building blocks.

New tuberculosis vaccine – MVA85A.

The OrganOx metra is the first and only fully automated normothermic liver perfusion device for improved organ preservation. The OrganOx pipeline products will extend the use of their core technology to the preservation of other organs.

Using leading edge human biomimetic platforms to test and develop therapeutics for serious human diseases.

A biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases.

Tissue expander solutions for the primary use in reconstructive and dental surgery.

Pioneering biomarker technologies for cancer therapies.

Developing tiny metallic mesh tube devices to treat patients suffering from brain aneurysms.

Peptide display company identifying potential peptide drugs for a range of chronic diseases

Developing a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine.

Nanoparticles for cancer therapy, imaging and drug delivery.

Cellular immunity vaccines.

Offering the most accurate assessment of running biomechanics that modern science is able to provide.

A rapidly grown, energetic company specialising in translational and regenerative medicine.

A private biopharmaceutical company focused on the development of therapies for retinal dystrophies. NightStar Therapeutics was acquired by Biogen in June 2019.

Designer Carbon Materials, Developing advanced nanomaterials for a range of applications, including energy harvesting, bio-sensing and quantum nanoelectronics.

Developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Their vision is to ultimately produce tissues that can be used in the clinic for organ repair or replacement.

Personalised cash grants to help people out of homelessness for good. £1,319 spent by Greater Change unlocks £35,177 in cost savings to the government. A return of over 20x.

A US non-profit which aims to provide education and tools for preventing public health crises and pandemics and to strengthen global public health preparedness

A new approach to automatic speech recognition technology.

All-in-one recruitment platform with video capacity.

Software to train radiologists.

Parallel hardware/software design.

Augmented reality cybersecurity assistant.

Cocotec builds software tools, which harness the power of automated formal verification. Its product, the Coco Platform, comes with a powerful software development environment that enables developers to build their software, automatically verify whether it is correct, and then generate high quality reliable code.

"CRIS" software that enables submission, de-identification and sharing of mental health patient records using a federated data and information governance model.

High performance quantum computing

Web-based healthcare knowledge.

Medical software

Computer game language development software.

A software development company that produce clinical trial data. In 2005 Third Phase Ltd merged with the Cmed Group Ltd. Third Phase Limited Merges with Cmed Group October 2005.

Software/hardware solutions

Company developing AI-based learning support applications.

Cybersecurity in a post quantum world

DeepReason.ai offers a Knowledge Graph Management System that can integrate seamlessly with various enterprise, and public, data sources to perform fast and intelligent reasoning

Low cost three dimensional imaging of museum artifacts.

Inkpath is a skills tracking app which helps it's users plan and track their career development in a smart format.

Developing RDFox, the world’s most powerful market-ready knowledge graph and semantic reasoner.

Software enabled system for orthopaedic care pathway management, implant safety monitoring and patient reported outcome delivery.

A broadcast personalisation engine to revolutionise audience experience.

DiffBlue is a world leader in automated test generation. Their products have been developed with industry partners over the last ten years and replace the manual process of writing tests.

SemmleCode is a line of products aimed to help developer teams improve their software quality.

Navetas is a UK based technology company delivering cloud-based energy monitoring and smart data analytics for the connected home.

A revolutionary new approach to indoor positioning that combines data from mobile phone sensors with map information such as floor plans, and wifi “maps” where available, to give highly accurate location information without the need for any further hardware.

A software that uses advanced algorithms and techniques to solve problems.

Data discovery software to manage and sort collections of images and data visually.

Domain-centric intelligent automated data extraction methodology.

OxCept is a team of security and communication experts creating military-grade authentication security products for business teams.

Develop cutting edge software applications that uncover the relationships between genetic variation and human disease.
Help pharmaceutical companies de-risk the drug development process.

Deontics is software which guides doctors and patients through the scientific and clinical decision making.

Using bio-inspired hydropower systems to generate power which is then converted to electricity.

Aims to identify and explore natural hydrogen sources.

Provides the tools you need to measure, report, and act on nature risks and opportunities, aligned with global regulations and standards.

Revolutionising the production of Fluorochemicals. A highly innovative, cost-effective and sustainable technology that removes the hazards of traditional fluorinating processes and supply chain.

Platform to promote critical thought on India and British Indians.

To improve the ESG outcomes of publicly traded corporations by enhancing the efficacy of shareholder ownership rights.

Social enterprise focusing on assessment of the ecological impact of industry supply chain and manufacturing and associated remedations.

To provide data curation and maintenance services to commercial entities involved in carbon offset markets.

To optimise the catalyst performance and highlight the advantages of a catalyst to create green fuel for the aviation sector through carbon capture.

Carbon-free transformation of ammonia waste.

Behaviour-based analytics.

Promote a culture of responsible research and innovation in information and communications technology and other areas of technology, research and innovation through its support for, continuation and expansion of the Observatory for Responsible Research and Innovation project.

The company develops analysis and decision support systems for marketing leaders, creating tools which are integrated into those offered by marketing research companies.

Work with major marketing insights companies in order to develop their marketing products.

Educational IT.

Proteomics.

Chemical information management.

Pollination.

Harness connections, promote collaboration and deliver practical projects for social impact.

The company uses quantum mechanics to generate verified truly random numbers.

OxVent Limited is a joint-venture social enterprise that will license the OxVent ventilator design for international deployment in Covid19 and beyond, and provide consultancy on its testing, regulatory approval and manufacturing.

Global Campus supports sustainable, integrated and interuniversity learning opportunities, reinvesting profits in scholarships for students and/or building capacity in local heritage structures.

OpenClinical’s transparent AI care apps present the right pathway for each case, and explain every decision

Research and experimental development on biotechnology.

Expertise and knowledge regarding data privacy, ethics, data security and public policy in connection with technology use.

Development of a platform for the standardisation of assetments to facility language, reading and arithmetic skills in children.

Improving the lives of people living with Parkinson’s.

High heat flux technology. The company will provide advanced engineering solutions to challenging thermal problems such as those that occur in fusion reactors, or high power density electronic systems.

To develop commercially scalable manufacturing process for spinning spider silk.

Controlling insects that spread disease.

Specialised archaeological-based IT applications.

Strategy gaming and consultancy

Genetic Genealogy

GPS tracking and monitoring technology.

Vigilance monitoring systems.

Advanced materials business which licences patents related to nanomaterials.

To develop compound libraries based on the asymmetric synthesis methodolofies.

Big data and analysis company focused on enabling reproducibility in chemistry.

Breath analysis.

Provide an environmentally-responsible method of controlling disease spreading pests.

A not for profit company providing a solution and accreditation to businesses that work to bring their workforce out of multidimensional poverty

LED spin-out using Perovskite technology.

A company being established to commercialise Zooniverse technology

Sensor technology based on optical microcavities used in scientific instruments and chemical sensors.

Development of geothermal technologies

Catalyst production and processes for upgrading pyrolysis oil to high octane gasoline.

Maritime trade and transport simulation.

Ubiquitous wireless power and data using metamaterials.

Develop technologies that miniaturise fluid handling to accelerate drug discovery.

Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

Velocys, previously Oxford Catalysts, produces speciality catalysts for the generation of clean fuels, from both conventional fossil fuels and renewable sources such as biomass.

Oxidative Enzymes for the Pulp and Paper Industry.

Advanced materials and technologies in safe, lightweight, high performance hydrogen storage technology.

Develops and manufacturers multispectral digital scanners based upon a patented flatbed scanner design.

Developing high performance scientific imaging detectors capable of studying structures and processes at the atomic level.

Develops and commercialises enzymatic process technologies that yield high-value chemical compounds.

Diagnostics built on a Raman-spectroscopy-powered single cell identification for bacteria and fungi.

Aim to deliver rapid diagnosis of inherited blood disorders, infectious diseases and early-stage cancer in sub-Saharan Africa.

Drug/Vaccine Delivery.

Sensor development.

Image analysis.

Malaria vaccine development.

Oxford Digital Innovation encompasses three different products. Two of them are online health records platform which aim to integrate NHS data (Zygote – IVF platform – and Simba – maternity platform). The 3rd platform is a virtual hospital which is aimed at scheduling appointments for patients and enable online consultations in specific specialisations, starting with eye care, skin care, pathology and dental medicine.

Water quality monitoring devices based on electrochemical (bio)sensors.

Gene/Drug Development

Software development for a novel biomarker to detect coronary heart disease.

Echo Machine Learning Assay

Virtual Reality software to help treat people with severe paranoia by allowing them to face situations that they fear.

The OxSight ‘SmartSpecs’ help sight impaired and blind people to navigate independently, avoid collisions and see in the dark.

Specialise in applying state-of-the-art mass spectrometry platforms to characterising intact protein assemblies, often referred to as native mass spectrometry.

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. In 2021, Oxford Immunotec was acquired by PerkinElmer.

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.

Oxford Medistress is commercialising a novel in vitro blood test device which aims to provide the first objective, quantitative measurement of stress.

Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Oxtox develops medical devices for the detection of specific drugs in the human system.

Eykona develops state-of-the-art imaging solutions to capture dermal characteristics and shape from the human body.

Intelligent Ultrasound develops and sells products and services that make medical ultrasound imaging a more effective diagnostic tool and help hospitals provide a better quality, more consistent ultrasound imaging service for their patients.

Revolutionary healthcare technology that measures medical vital signs without physical contact.

Developing tiny metallic mesh tube devices to treat patients suffering from brain aneurysms.

Their system uses electromagnetic and acoustic waves to create a new class of medical images at a cost comparable to ultrasound.

Developing solutions for major unmet needs in diagnostic medicine in multiple internal organs. In the first instance the focus will be on, the detection and the accurate, quantitative measurement of liver, gallbladder and pancreatic disease, including precancerous and cancerous states in these organs.

OxSonics provide economic and scalable life-changing treatments to solid tumour cancer patients.

Weaving perfect components into quantum technology solutions.

Help customers obtain high-purity metals from their waste or process streams in a simple & highly profitable manor and achieve sustainability goals by removing toxic metals from wastewater.

High-speed Vision, LIDAR and IMU tracking/odometry and mapping.

Cutting edge laser technology company.

A lean spin-out, social enterprise focusing on developing a fast rapid COVID-19 test. Joint Oxford University and OSCAR company.

Custom made helmet using 3D printing.

Energy from Fusion.

Development of asthma monitoring system

AR/AV platform technology for software industry. 6D.ai was aquired by Niantic in March 2020.

Electrical and software controls for lithium ion battery storage.

Laser fabrication in diamond structures.

Next generation of high performance alloys.

Maritime trade and transport simulation.

Proxisense specialise in advanced sensors, diagnostics and optimisation systems to prevent downtime & equipment failure. They improve performance & efficiency of complex rotating equipment.

Robust, networked sensors for oilfield machinery, drilling and metering.

Aurox was established to research, develop, manufacture and commercially exploit products in the field of confocal microscopy and automated pathology slide scanners.

YASA Motors manufactures a highly differentiated advanced axial flux motor and generator based on its proprietary Yokeless And Segmented Armature (YASA™) technology.

Oxford Electromagnetic Solutions - smart asset management through underground network visibility.

Kepler Energy Limited develops a second-generation tidal turbine, which has the potential to harness tidal energy more efficiently and cheaply, using a device which is simpler, more robust and more scalable than current designs.

Oxford PV are developing new photovoltaic cells that will provide a sustainable solar energy source.

Advanced materials and technologies in safe, lightweight, high performance hydrogen storage technology.

Developing domestic energy storage capacity and facilitating its operation within the existing power distribution infrastructure.

Oxford Flow’s industrial pressure regulators use innovative technology to provide new levels of performance for natural gas transmission, water distribution and process industries.

Oxbotica. Robotics, autonomous systems, driverless pods.

Machine learning and AI algorithms.

Methods and systems for performing multiplication operations in waveguides using photonic switching elements.

Technology products and services.

Laser Devices.

Automotive components.

To bring the tools developed for heritage to the management of healthcare data.

3D laser spectrometer and single shot hyperspectral imaging.

Cocotec builds software tools, which harness the power of automated formal verification. Its product, the Coco Platform, comes with a powerful software development environment that enables developers to build their software, automatically verify whether it is correct, and then generate high quality reliable code.

building a scalable, modular and flexible quantum computing platform.

Development and commercialisation of quantum physics, acceleration and optimisation software for intelligent computational R&D.

Light-emitting materials. In 2002 Opsys Ltd was acquired by Cambridge Display.

State-of-the-art machine learning technology for autonomous vehicles and traffic modeling applications. Latent Logic was acquired by Waymo in December 2019.

Silicon-based quantum computing.

Developing superconducting circuit quantum computing.

Maritime trade and transport simulation.

Ubiquitous wireless power and data using metamaterials.

Oxford Nanoimaging’s microscope, the Nanoimager, is a single-molecule fluorescence microscope.
It is about 30 times smaller and significantly less expensive than current super-resolution microscopes and will be manufactured in the UK.

Specialise in applying state-of-the-art mass spectrometry platforms to characterising intact protein assemblies, often referred to as native mass spectrometry.

Oxbridge Pulsar Sources (OPS) is researching and developing novel radio transmitting antennas, based on new principles.

Oxford Advanced Surfaces develops and commercialises advanced materials and technology solutions leveraging breakthrough surface modification technology.

Oxford PV are developing new photovoltaic cells that will provide a sustainable solar energy source.

Advanced materials and technologies in safe, lightweight, high performance hydrogen storage technology.

Tissue expander solutions for the primary use in reconstructive and dental surgery.

Develops and manufacturers multispectral digital scanners based upon a patented flatbed scanner design.

Developing high performance scientific imaging detectors capable of studying structures and processes at the atomic level.

Animal Dynamics marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from our environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering.

Using phase change materials for smart glazing and displays.

Oxbotica. Robotics, autonomous systems, driverless pods.

OxCo produces videos in collaboration with researchers, teaches academics how to leverage video technologies, and convenes unique hybrid events.

Design and manufacture accelerator graphical cards for datacenters.

Digital health company focused on neurodegenerative diseases.

Oxvalue.ai offers a useful new approach for appraising technology, and an important guide for decision-making in technology investment, transfer and commercialisation.

Provides advanced insights on global information operations, data flows, and public understanding of critical issues.

Digital CBTe software.

Reg Metrics - Regulatory compliance software, that enables health innovation.

Machine learning algorithm and codes for quantum computers.

Developing international trade and transport simulators, using mathematical models and machine learning.

A B2B tech platform for clothing retailers to make fit & style accessible to more people, leveraging computer vision, and deep learning. AISTETIC is aiming to reduce online returns and increase conversion for retailers.

LitHits is a novel way to encourage people to read and engage with literature through their mobile phone via the LitHits app.

Aim is to accelerate and streamline research through an innovative digital platform for knowledge sharing.

Mining large digital pathology datasets through a web platform that can manage a crowd sourced approach to annotation.

Interactive character animation.

Maritime trade and transport simulation.

A broadcast personalisation engine to revolutionise audience experience.

Develop technologies that miniaturise fluid handling to accelerate drug discovery.

Oxford Risk is the market-leading provider of customer risk profilers. Their products reveal the level of risk customers are willing and able to take with their financial investments.

A revolutionary new approach to indoor positioning that combines data from mobile phone sensors with map information such as floor plans, and wifi “maps” where available, to give highly accurate location information without the need for any further hardware.

Data discovery software to manage and sort collections of images and data visually.